VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is expanding its use of human-relevant testing methods across its oncology research programs, seeking to generate more clinically informative preclinical data while reducing the number of animals required for drug development. The Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., outlined its implementation of New Approach Methodologies (NAMs), a collection of non-animal research techniques that includes cell-based assays, computational modeling and three-dimensional spheroid models, according to an October 7, 2026, company announcement.
The strategic shift matters because preclinical studies that rely on traditional animal models often fail to predict human responses, contributing to high attrition rates in oncology drug development. By adopting NAMs, VERAXA aims to improve the translational relevance of its experimental findings while aligning with FDA guidance that encourages alternatives to animal testing. The company says the approach supports development of its BiTAC® T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for the treatment of cancer.
New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. In an ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, the company required about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. VERAXA says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. The reduction in animal use—roughly 95% fewer mice in this instance—highlights both ethical and efficiency gains that could shorten development timelines and lower costs.
For investors, the announcement signals a potential competitive advantage: human-relevant testing may yield more reliable efficacy and safety signals earlier, helping VERAXA prioritize candidates with the greatest chance of clinical success. The company’s pipeline of T-cell engagers and antibody-drug conjugates targets hard-to-treat cancers, where predictive models are especially critical. As regulators increasingly embrace NAMs, VERAXA’s proactive adoption could position it favorably for future FDA interactions and partnerships. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
VERAXA Biotech (NASDAQ: VRXA) continues to advance its mission to design novel cancer therapies, and the expanded testing strategy underscores its commitment to innovation that is both scientifically robust and ethically responsible. For a deeper look at the announcement, see the full Read More>> coverage. The company’s progress is closely followed through platforms such as MissionIR, which provides syndicated content to enhance visibility within the investment community. MissionIR is part of the Dynamic Brand Portfolio at IBN, delivering access to wire solutions via InvestorWire and editorial syndication to over 5,000 outlets, among other services. As VERAXA integrates NAMs across its programs, the implications extend beyond animal welfare: the move could enhance the predictability of its preclinical data, potentially accelerating the path to human trials for its antibody-based cancer pipeline.
